Spero Therapeutics Inc (SPRO) Receives $27.75 Consensus Price Target from Analysts
Spero Therapeutics Inc (NASDAQ:SPRO) has been given a consensus rating of “Buy” by the eight brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $24.40.
Several research firms recently commented on SPRO. Oppenheimer set a $30.00 target price on Spero Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 9th. Cantor Fitzgerald set a $27.00 target price on Spero Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 9th. Finally, Zacks Investment Research raised Spero Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Wednesday, August 15th.
In other news, major shareholder Plc Glaxosmithkline acquired 80,000 shares of Spero Therapeutics stock in a transaction on Tuesday, July 17th. The stock was purchased at an average price of $12.50 per share, with a total value of $1,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 26.90% of the company’s stock.
Shares of SPRO stock traded down $0.48 on Wednesday, hitting $9.60. The company had a trading volume of 103,220 shares, compared to its average volume of 82,455. The stock has a market cap of $190.95 million and a price-to-earnings ratio of -0.54. Spero Therapeutics has a twelve month low of $9.29 and a twelve month high of $19.00.
Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Thursday, August 9th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.08. Spero Therapeutics had a negative return on equity of 132.11% and a negative net margin of 1,479.91%. The business had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.62 million. As a group, equities analysts forecast that Spero Therapeutics will post -2.87 earnings per share for the current year.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.